Expertise in
19
conditions

Dr. Benjamin A. Weinberg

Oncology
MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital
3800 Reservoir Rd NW, 
Washington, DC 
Accepting New Patients
Offers Telehealth
Expertise in
19
conditions
MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital
3800 Reservoir Rd NW, 
Washington, DC 

Overview

Benjamin Weinberg is an Oncologist practicing medicine in Washington, Washington, D.c..

Dr. Weinberg is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Pancreaticoduodenectomy, and Vertebroplasty.

He is actively involved in clinical research, co-authoring 77 peer reviewed articles and participating in 16 clinical trials. Dr. Weinberg is currently accepting new patients.

Specialties

Oncology

Hospital Affiliations

Medstar Georgetown University Hospital
Medstar Washington Hospital Center
Medstar Montgomery Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer
NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Phase: Phase 2
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
Phase I Study of Proton Therapy in Adjuvant Pancreatic Cancer (Proton-PANC)
Phase I Study of Proton Therapy in Adjuvant Pancreatic Cancer (Proton-PANC)
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Drug, Radiation
Study Drug: mFOLFIRINOX
Study Phase: Phase 1
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Enrollment Status: Active_not_recruiting
Publish Date: September 27, 2024
Intervention Type: Biological, Drug
Study Drugs: Cetuximab, Irinotecan, Panitumumab, Regorafenib
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
View 9 Less Clinical Trials

77 Total Publications

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.
Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.
Journal: Research square
Published: July 10, 2026
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (0.1 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Cheson is an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Cheson is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Non-Hodgkin Lymphoma. Dr. Cheson is currently accepting new patients.

Expertise in
18
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Expertise in
18
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Referral may be required

Office

8906 Bradmoor Dr, 
Bethesda, MD 
 (6.7 miles away)
301-496-7387
Languages Spoken:
English

Brigitte Widemann is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Widemann is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Medullary Thyroid Carcinoma, and Thyroidectomy.

Expertise in
12
conditions
Dr. David H. Vesole
Oncology | Hematology
Expertise in
12
conditions
Dr. David H. Vesole
Oncology | Hematology
Referral may be required
Before you request

MedStar Georgetown University Hospital

3800 Reservoir Road Northwest, 
Washington, DC 
 (0.3 miles away)
551-996-8704
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Vesole is an Oncologist and a Hematologist practicing medicine in Washington, Washington, D.c.. Dr. Vesole is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant. Dr. Vesole is board certified in American Board Of Internal Medicine. Dr. Vesole is currently accepting new patients.

Frequently Asked Questions about Dr. Benjamin A. Weinberg

How do I make an appointment with Dr. Benjamin A. Weinberg?

You can book an appointment with Dr. Benjamin A. Weinberg by calling their office at 202-444-2223. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Benjamin A. Weinberg a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Benjamin A. Weinberg is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Benjamin A. Weinberg specialize in?

While Dr. Benjamin A. Weinberg is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Benjamin A. Weinberg participate in research or clinical trials?

Yes. Dr. Benjamin A. Weinberg has published 77 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Benjamin A. Weinberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Benjamin A. Weinberg accept my insurance?

Dr. Benjamin A. Weinberg accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 202-444-2223 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weinberg's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile